Arrowhead Pharmaceuticals Establishes Verona, Wisconsin, Campus
05/10/2022
The new campus, which will consist of two buildings, will complement the company’s existing 111,000-square-foot research and development facility in Madison.
The first building is an approximately 125,000-square-foot laboratory and office facility that will support process development and analytical activities. The second is an approximately 160,000-square-foot GMP drug manufacturing facility, which company leaders say will be critical to Arrowhead’s global operations.
“We have seen firsthand the tremendous value that the Wisconsin biotech ecosystem can afford a nimble and aggressive company like Arrowhead,” said Christopher Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals. “The local community has supported us graciously over the last decade, so we look forward to this expansion contributing to the further growth in the region as we work to make medicines with a potential global impact.”
Wisconsin Economic Development Corporation (WEDC) is assisting Arrowhead Pharmaceuticals with $2.5 million in performance-based business development tax credits, which the company will receive if it meets or exceeds job creation and capital investment goals by the end of 2026. The city of Verona is also assisting the project with up to $16 million in tax incremental financing for site improvements.
“WEDC is pleased to partner with Arrowhead because they have the potential to transform health care, and all of our lives, through innovation, persistence, and collaboration,” said Missy Hughes, secretary and CEO of WEDC. “Arrowhead joins a growing list of biopharmaceutical companies that have chosen to locate in Wisconsin because of the strategic investments our state has made in worker education and training, infrastructure, and strong communities in recent years.”
Based in Pasadena, California, Arrowhead Pharmaceuticals is developing new medicines for intractable diseases by silencing the genes that cause them. It does this by tapping into a process called RNA interference, or RNAi. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.
Project Announcements
Amazon Plans Goochland County, Virginia, Fulfillment Operations
05/16/2025
Reworld Plans Park Hills, Missouri, Material Processing Operations
05/16/2025
Sumitomo Drive Technologies Upgrades Chesapeake, Virginia, Warehouse-Distribution Operations
05/16/2025
Green Recycle USA Plans Pittsylvania County, Virginia, Operations
05/16/2025
QualiChem Expands Salem, Virginia, Operations
05/16/2025
Turkey-Based Mega Metal Plans Ridgeway, South Carolina, Manufacturing Operations
05/16/2025
Most Read
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and
Q2 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025